NEWRON PHARMACEUT. EO-20 (NP5) — Capital Reinvestment Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow (€32.35 Million) in capital expenditures (€48.00K). Check how tangible is NEWRON PHARMACEUT. EO-20's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
NEWRON PHARMACEUT. EO-20 Capital Reinvestment Ratio (2025–2025)
This chart tracks NEWRON PHARMACEUT. EO-20's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see NP5 operating cash flow.
Annual Capital Reinvestment Ratio for NEWRON PHARMACEUT. EO-20 (2025–2025)
Year-by-year Capital Reinvestment Ratio for NEWRON PHARMACEUT. EO-20 from 2025 to 2025. See how much free cash does NEWRON PHARMACEUT. EO-20 generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | €32.35 Million | €48.00K | — |